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Purpose: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication 
adherence, while also determining whether or not altering the functionality of the DA in three 
randomized subject groups can reduce observer effect.
Methods: Forty-five subjects were randomized into three groups: two with monitored DAs 
and one without monitoring. One group of subjects was given a DA that both monitored drop 
usage and had visual and audible alarms, while the other monitored group included subjects 
given a DA that had no alarms but continued to monitor drop usage. The third group was given 
a DA that had no alarm reminders or dose usage monitoring. Subjects were informed that some 
monitors would not be functional, in an attempt to reduce observer effect, or the effect of being 
monitored on subject behavior and adherence. A six-item questionnaire was also utilized to 
assess how the subjects felt about their adherence and DA use.
Results: The overall adherence rates were found to be 78% in the fully functional group 
(95% confidence interval: 70–88) and 76% in the no alarms group (95% confidence interval: 
65–89). No association was seen between questionnaire response and medication adherence. 
The patients in the DA group without alarms had a significantly higher odds ratio of medica-
tion adherence if they reported on the questionnaire that using the DA did affect how much 
they used their drops.
Conclusion: Though the use of DA was expected to reveal different rates of adherence 
depending on the functionality of the DA between groups, patients with a nonfunctioning DA 
did not have a significant difference in medication adherence compared to those given a fully 
functional DA. This supports that an observer effect was not reduced despite these interven-
tions, and that the subjects adhered to taking their medications as if they had a functioning DA 
and were being monitored.
Keywords: dosing aid, observer effect, glaucoma, adherence
Introduction
Glaucoma is a chronic, optic neuropathy characterized by optic nerve damage, visual 
field defects, elevated intraocular pressure, and progressive vision loss that impacts 
60 million people worldwide.1 Glaucoma management typically includes a daily 
eyedrop regimen.2,3 When properly used, eyedrop medication can effectively lower 
intraocular pressure, reduce optic nerve deterioration, preserve vision, and prevent 
glaucomatous blindness. However, rates of medication adherence and persistence 
(ie, continued use of medication over time) are especially low among patients diag-
nosed with glaucoma.4–6 Electronic monitoring of glaucoma medication administration 
found that adherence rates were poor.7–9 Okeke et al found that among patients being 
provided free medication for once-daily dosing who knew they were being monitored, 
45% used their eyedrops less than 75% of the time. Further, close to one fifth of 
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Okeke et al’s subjects (19.4%) used eyedrops less than 50% 
of the time.6 Prospective randomized trials on the impact of 
adherence on clinical outcomes in glaucoma are lacking.
Foucault wrote in his work on prison construction about 
the effect of monitoring on behavior.7 Ideally, he suggested, 
prisons should be constructed in such a way that monitoring 
is possible at all times but that the prisoner should not be able 
to tell at what point he is being monitored. He states that if 
a prisoner cannot tell whether or not he is being monitored, 
he will behave as if he is being monitored at all times. He 
coined the term “panopticism” for this effect.7
Clinical trials are performed to guide clinical practice, 
but the nature of a clinical trial may include biases that 
differ from clinical practice. Observer effect, reactivity, 
and “guinea pig” effect are some of the names given to the 
way observation influences the behavior of study subjects. 
Given that adherence to medications remains an important 
issue in medical treatment,2,3 it is important to explore 
the unobserved, or “real”, medication adherence habits of 
patients with glaucoma. However, the evolution of ethical 
considerations and increasingly strict regulations governing 
clinical trials make it inappropriate to collect data on patients 
without their knowledge. With these considerations in mind, 
we designed a study to assess eyedrop medication adherence 
using a Travoprost Dosing Aid (DA), in an attempt to reduce 
observer effect. 
Methods and design 
study organization
Forty-five subjects were randomly assigned to one of three 
groups by a predetermined three-way randomization chart: 
a “functional DA group” (Group 1) consisting of 20 participants 
who were given fully functioning DA devices with visual and 
audible alarms as dosing reminders and drop usage recording 
turned on (Alcon Laboratories, Inc., Fort Worth, TX, USA); 
a “no DA alarms group” (Group 2) consisting of 20 participants 
who were given DAs with disabled visual and audible alarms 
but that still monitored drop usage (ie, silent monitors); and 
a “nonfunctional DA group” (Group 3) consisting of five 
participants given nonfunctioning, placebo devices with 
visual and audible alarms disabled, and monitoring disabled. 
Subjects were informed that not all patients would be moni-
tored. Groups 2 and 3 were given devices without audible 
or visual alarms to introduce doubt as to whether or not they 
were being monitored. All subjects were told at baseline that 
some of the devices were nonfunctional. Thus, the patients 
in Groups 2 and 3 were masked to whether or not they were 
being monitored on dose usage. 
Patient study involvement
All subjects were given travoprost medication and trained 
on how to place the travoprost bottle in the DA and how to 
depress the lever arm to deliver a drop. Subjects were told 
that, when functioning, the device records usage when the 
lever is depressed. Subjects were asked to specify a 2-hour 
window during which they intended to use the medication 
each evening for which the functional DAs were set to trig-
ger alarms. The subjects were supplied with free medication 
during the study period. Subjects returned in 6 weeks and the 
information was downloaded from each device and compiled 
in an identity-masked database. The subjects filled out a brief, 
non-validated six-item questionnaire on their perceptions of 
the device, including whether or not they believed their own 
device was functional. The questionnaire was intended to 
help us gain some potential insight into subjects’ behaviors 
and perceptions after utilization of the DA.
subjects and eligibility criteria
A total of 45 subjects were included, 20 in each monitored 
group and five in the unmonitored group. Inclusion criteria 
allowed for subjects with any type of glaucoma or glaucoma 
suspect diagnoses, treated with one or more glaucoma medica-
tions that included a topical prostaglandin analog. The number 
of patients chosen for each group was based on how many 
patients were interested in participating who fit the eligibility 
criteria for the duration of the study. The main exclusion crite-
ria were mental and physical disabilities of subjects, including 
poor vision, precluding usage of the device and medication 
adherence. Patients were also excluded if they were unable to 
understand the study, if they did not instill their own drops, or 
if they were incapable of using the DA after a brief demonstra-
tion. All eligible patients had to be 18 years of age or older.
The study was reviewed by the Sidney Kimmel Medical 
College Institutional Review Board and deemed in concor-
dance with the provisions of the Declaration of Helsinki and 
was registered in the NIH public database. Written informed 
consent was obtained.
DA
The DA can provide data only on use of the topical pros-
taglandin analog travoprost, because no other bottles for 
glaucoma medications fit within it. A bottle of travoprost 
is placed in the device and a lever is used to squeeze out a 
drop. A built-in memory chip records the time and date when 
the lever is depressed. The DA also has visual and audible 
reminders that can be set to remind patients to take their drops 
in a specified time period daily. Data can be downloaded to 
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assess whether or not a patient adhered to drop usage on a 
given day.1 Because the device has the potential to make 
extra recordings when the lever is depressed accidentally, 
eg, if more than one dose is used to ensure instillation within 
the eye, more than one dose taken per eye per day was not 
counted in the adherence rate calculation (travoprost is 
indicated for once-daily use). When the lever was depressed 
outside the time window, it was assumed that a dose was not 
taken, and when the lever was depressed multiple times in 
the time window, only a single dose was assumed to have 
been delivered.10
Outcome measures
The primary outcome was medication adherence, defined as 
any use of eyedrops on a given day. The secondary outcome 
was awareness of monitoring. Medication adherence was 
based on the DA data and secondary questionnaire. This 
questionnaire was an instrument created for this study with 
no previous validity evidence, with adherence rated using 
a single yes/no question. The survey implemented patient 
awareness of monitoring as a second self-report measure that 
was documented by either a yes or no to each question.
statistical analysis
Poisson regression with robust standard errors was used 
to model the relative risk of adherence while accounting 
for correlation among multiple measurements from the 
same subject. A first-order autoregressive structure was 
assumed for the working correlation structure.11,12 Logistic 
regression analysis was used to test for association between 
questionnaire response and adherence. The group to which 
subjects were assigned and their questionnaire responses 
were assessed and included as covariates in the logistic 
regression model to determine whether there was an associa-
tion. Exact chi-square tests were used to look for differences 
among groups with respect to questionnaire responses. In a 
sensitivity analysis, both sets of models were repeated using 
only the first 15 days of follow-up to ensure equal amounts 
of data for each subject because some subjects did not 
complete the 6-week course. In this way, we also examined 
both adherence and short-term persistence. All analyses 
were performed using SAS version 9.1 (SAS Institute Inc., 
Cary, NC, USA). 
Results
Baseline characteristics
Forty-five subjects (age: 67.6 years [standard deviation: 
12.1]; 47% male) with a variety of glaucoma diagnoses 
were recruited, more than half of which were on travoprost 
monotherapy prior to the study, the others were changed to 
travoprost for the study (Table 1). All but one (who died) 
completed the questionnaire. In the “functional DA group” 
one device malfunctioned. In the “no DA alarms group”, two 
devices were never returned despite persistent attempts to 
obtain these, and three devices malfunctioned. The malfunc-
tioning devices showed no data recorded after the first day, 
and were returned to the manufacturer (Alcon Laboratories, 
Inc.) who was also unable to retrieve data from these or to 
determine the reason for the absence of data. 
Patient adherence
Overall average medication adherence, defined as taking the 
eyedrops on a given day, was 78% of doses (95% confidence 
interval [CI]: 71%–85%). Adherence was nearly identical in 
both groups: 78% adherence in the “functional DA group” 
(95% CI: 70%–88%) and 76% adherence in the “no DA 
alarms group” (95% CI: 65–89). The relative risk of adher-
ence comparing the “functional DA group” to “no DA alarms 
group” was 1.03 with a 95% CI of 0.85, 1.25 (P=0.76). In 
case reduced adherence over time in both groups was a factor, 
the first 15 days of therapy were assessed. Results differed 
slightly when considering only the first 15 days of data for 
each subject. The adherence for the first 15 days was 81% 
(95% CI: 74–89). Adherence did not significantly (statisti-
cally) differ between groups. There was 85% adherence 
in the “functional DA group” (95% CI: 78–93) and 76% 
adherence in the “no DA alarms group” (95% CI: 64–91). 
The relative risk of adherence comparing these two groups 
was 1.11 (95% CI of 0.91–1.36) (P=0.29). The functional 
Table 1 study group characteristics 
Characteristics Functional 
DA group
(Group 1)
No DA 
alarms group 
(Group 2)
Nonfunctional 
DA group  
(Group 3)
Male/female patients 8/12 9/11 4/1
Age in years:  
mean ± sD
68.15±12.77 66.26±11.1 66.8±14.62
race: AA, c, A 6, 13, 1 8, 11, 1 3, 1, 1
POAg 11 11 2
number of medications
Only 1 9 17 1
Two 6 2 2
Three 5 1 2
Dropout reasons 1 died 3 device 
malfunctions,  
2 devices unable 
to recover data
none
Abbreviations: sD, standard deviation; AA, African American; c, caucasian; 
A, Asian; POAg, primary open angle glaucoma; DA, Travoprost Dosing Aid.
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DA group had slightly but nonsignificantly higher adherence 
than the no DA alarms group. 
Adherence within a 2-hour window 
of the time of planned dosing
Another planned evaluation was use of the medication 
within an hour before or after subject’s chosen time of 
dosage. Overall adherence within this window was 42% 
(95% CI: 34–54). Adherence within 2 hours was higher in the 
fully functional group than in the no alarms group: 51%; (95% 
CI: 40–65) vs 31% (95% CI: 20–48), although the differ-
ence was not statistically significant (P.0.05). The relative 
risk of adherence within 2 hours was 1.63 (95% CI: 1–2.68) 
(P=0.052). In the first 15 days, adherence within a 2-hour 
window of the planned dosage was 43% (95% CI: 33–56) for 
all groups together. Again, adherence was higher in the 
fully functional group (55%; 95% CI: 42–73) than in the 
alarms only group (29%; 95% CI: 18–47). The relative 
risk was 1.89 favoring greater adherence in the first group 
(95% CI: 1.08–3.30 [P=0.025]). These data suggest that the 
group with functional visible and audible alarms were more 
timely in their dosing in the first 15 days of the study.
Actual and self-reported medication 
adherence
Subjects in the “no DA alarms group” were more likely to 
admit to not administering eyedrops and were much less 
likely to agree that the DA affected how much they used 
their drops (see Table 2, questions 1 and 4). In Group 1, the 
“functional DA group”, 95% of subjects reported missing 
less than one drop per week on average, but the DA record-
ings showed only 30% to have missed less than one drop per 
week. For Group 2, the “no DA alarms group”, these numbers 
were 68% by self-report and 30% by DA.
Participants in the “nonfunctional DA group” were less 
likely to think that their DA was functioning (40%), although 
the difference was not statistically significant (P=0.20), and 
most patients in the other two groups felt that they were 
being monitored (80% and 74%). Eighty percent of subjects 
in Group 3 felt the DA affected their drop use, which was 
statistically significant compared to the other two groups. 
Patient adherence and the 
questionnaire responses
The increased adherence in patients who believed that they 
were being monitored was not statistically significant. There 
was no association between questionnaire response and 
adherence (see Table 3: odds ratios greater than 1 indicate 
that adherence was higher for those patients answering “yes” 
to the questions, while odds ratios less than 1 indicate that 
adherence was higher for patients answering “no” to the ques-
tions). The only statistically significant association was that 
patients in the “no DA alarms group” had a slightly higher 
odds ratio of adherence if they reported that using the DA 
affected how much they used their drops.
Discussion
It was initially hypothesized that adherence rates would be 
different in each group, depending on the modifications made 
to the DA and whether, as a result, a patient would feel as 
if he or she was being monitored. Adherence was not sta-
tistically different between the “functional DA group” with 
functioning visible and audible dosing alarm reminders, and 
the “no DA alarms group”. A similar percentage of patients 
suspected they were being monitored in both of these groups 
despite that those in Group 2 were given a DA that had no 
alarm reminders for the subjects. This supports that even 
without reminder alarms, subjects still adhered in a similar 
fashion to those with the reminder alarms. This, along with 
the questionnaire, substantiates that altering the presence 
of reminders on the DA did not significantly reduce subject 
perceptions of being observed/monitored.
Table 2 Association of group membership and questionnaire response
Question Number (%) with positive response P-value for exact 
chi-square test of 
differences among 
three groups
Group 1 
(n=20)
Group 2 
(n=19)
Group 3 
(n=5)
1. Are you missing more than one drop per week on average? 1 (5) 6 (32) 0 (0) 0.056
2. Do you like the DA? 17 (85) 14 (74) 5 (100) 0.35
3. Do you feel as if you were monitored by the DA? 16 (80) 14 (74) 2 (40) 0.20
4. Did the DA affect your drop use? 10 (50) 4 (21) 4 (80) 0.029
5. Would you recommend the DA? 17 (85) 14 (74) 5 (100) 0.35
6. Would you continue to use the DA? 16 (80) 14 (74) 5 (100) 0.45
Notes: group 1: fully functional; group 2: no alarms; group 3: nonfunctional.
Abbreviation: DA, Travoprost Dosing Aid.
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According to the questionnaire, 74% of patients in 
Group 2 and 40% of patients in Group 3 felt they were being 
monitored (Table 2). Group 3 had a significant increase in 
medication adherence if they indicated that the DA improved 
their dose usage, though their DAs were nonfunctional. It 
appears that there was insufficient doubt about the monitor-
ing process among subjects, despite their being informed at 
baseline that some subjects would not be monitored. Actions 
such as turning off the visual and audible DA alarms or 
providing nonfunctional devices did not affect subjects’ 
perception of monitoring. 
lessons learned
This trial showed relationships between subject perception 
of monitoring and medication usage, an observer effect. 
Clinical trial results may be biased because subjects alter their 
behavior when they are monitored. In addition, patients’ self-
selection bias to enroll may also affect study results. These 
aspects should be considered when applying results to clinical 
practice. These issues have affected this study, despite efforts 
to convince subjects that they were not being monitored. This 
raises the possibility that a favorable outcome in a clinical 
trial may not directly translate into a favorable outcome for 
a patient in unobserved, “real” clinical practice. 
Another significant finding is the difference in self-reported 
adherence by questionnaire compared to actual adherence as 
recorded by the DA. For instance, 95% of Group 1 subjects 
indicated that they had not missed more than one drop on 
average, per week, while the DA indicated that this actu-
ally only was true for 30% of these subjects. It would be 
interesting for additional studies to explore the difference in 
self-reported adherence vs actual adherence and to assess in 
which populations those differences are the largest. 
In previous studies, patients reported far higher medica-
tion use than their actual behavior. Several reasons have been 
suggested for this, including patients wanting to please their 
physicians, patients not wanting to admit an error, or patients 
not feeling comfortable enough to admit their concerns 
with the medication.9 Reported levels of non-adherence are 
affected by environmental cues and the method of ques-
tioning. Patient self-report and DA data produced different 
estimates of adherence in the current study and the self-report 
numbers for adherence were higher. 
Although patient adherence can be assessed by indirect 
means (ie, interviewing, assessing pharmacy records), each 
of these has limitations. Electronic monitoring may be more 
accurate than any other option, but is also limited in that 
patients who know they are being monitored may change 
their behaviors as a result of the Hawthorne effect.13,14 
Although subjects were aware for the entire study period 
that they may have been monitored, many clinical trials have 
actually found poor adherence despite patients’ knowledge 
of monitoring, and often any effects that may be attributed to 
monitoring reactivity are transient. This could be explored in 
a study that follows patient adherence over a longer period 
of time than this study, to see if once subjects became accus-
tomed to being monitored, they act naturally.13,14
Interestingly, searches for other observation trials found 
behavioral studies of police that suggested that observation 
influences behavior but that over time this influence dimin-
ishes. This may be because the research subjects become 
accustomed to the observer and begin to act naturally. While 
Table 3 Association between responses to questionnaire and adherence by group
Question Group Odds ratio  
(adherence vs no 
adherence –  
yes vs no)
95% confidence interval P-value
Lower Upper
1. Are you missing more than one 
drop per week on average
1 1.11 0.62 1.97 0.73
2 0.57 0.28 1.16 0.12
2. Do you like the DA? 1 2.11 0.42 10.59 0.36
2 1.95 0.39 9.79 0.42
3. Do you feel as if you were 
monitored by the DA?
1 1.77 0.46 6.91 0.41
2 4.97 0.71 34.78 0.11
4. Do you feel that the DA affected 
your drop use?
1 1.33 0.45 3.88 0.60
2 3.07 1.10 8.59 0.03
5. Would you recommend the DA? 1 2.11 0.42 10.59 0.36
2 1.95 0.39 9.79 0.42
6. Would you continue using the DA? 1 2.11 0.42 10.59 0.36
2 1.95 0.39 9.79 0.42
Notes: group 1 (n=19): functional DA; group 2 (n=15): no DA alarms.
Abbreviation: DA, Travoprost Dosing Aid.
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clearly a different situation, this may explain the drop-off 
in adherence over a longer period of time. The similarity 
between the groups independent of time may be due to the 
fact that all of them, as indicated in the questionnaire, felt 
monitored to some extent.13–15 
limitations
The limitations of this study primarily were the small popu-
lation sizes in each randomized group and that not all of the 
dosing aids were returned or able to provide the necessary 
information regarding dose usage. It was also a limitation 
to assess a 2-hour window of adherence and it would be 
interesting to see if a larger window correlated better with 
patient perception and adherence. Additionally, there was no 
true non-monitored comparison group in this study, because 
all participants believed it was possible that their daily 
medication use was monitored. It would be worth repeat-
ing the study under conditions where the DA is not also the 
method for collecting adherence data: if pharmacy fill data 
were available as the measure of adherence, some patients 
were also given a DA, and others were not. The confound-
ing of the adherence measure with the monitoring device is 
a design problem that the current study could not solve. The 
self-report measure was a single, unvalidated item and more 
well-validated adherence self-report tools might produce 
different results. This study utilized the 2-hour window of 
patient adherence and questionnaire, but future studies may 
benefit by exploring additional metrics to assess adherence, 
such as other self-reported measures (such as the visual 
analog scale), or collecting the DA bottles and looking at 
the amount of medication left over.
Conclusion
It is both difficult and important to experiment with study 
designs that mitigate bias induced by artificial circumstances 
within a trial to achieve results that will reflect real clinical 
practice. This study suggests that the biases introduced by 
inclusion in a study may overwhelm deliberate attempts to 
induce doubt about observation.  
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